Per Artikel

Riset dan Pengabdian Masyarakat Do Research Sosial Service and Innovation

Id	Authors	Full Names	Author S Id	Title	Year	Source Title	Volume	Issue	Art No	Page Start	Page End	Page Count	Cited By	Link	Affiliations	Authors With Affiliations	Abstract	Author Keywords	Index Keywords	Funding Details	Funding Text	Publisher	Issn	Pubmed Id	Document Type	Sjr Best Quartile	Sjr	Sjr Rank
Display # Page 1 of 50 Start Prev 1 2 3 4 5 6 7 8 9 10 Next End
12764260600; 24070244600; 53663802900; 57221578995; 55839842000; 57192698934; 57193196381; 8088436500; 7006023235; 57197752505; 57193522866; 56693812000; 7201438906; 6508227376; 6602792356; 58434745100; 58910827500; 58910632700; 58910037700; 57219957155; 58349814100; 57194732282; 59157671700; 58911235000; 57205400013; 7005105717; 56653172200; 56230606500; 36440260400; 57535599600; 7005354286; 36103192800(1)
No records
269	Shitara K.; Fleitas T.; Kawakami H.; Curigliano G.; Narita Y.; Wang F.; Wardhani S.O.; Basade M.; Rha S.Y.; Wan Zamaniah W.I.; Sacdalan D.L.; Ng M.; Yeh K.H.; Sunpaweravong P.; Sirachainan E.; Chen M.-H.; Yong W.P.; Peneyra J.L.; Ibtisam M.N.; Lee K.-W.; Krishna V.; Pribadi R.R.; Li J.; Lui A.; Yoshino T.; Baba E.; Nakayama I.; Pentheroudakis G.; Shoji H.; Cervantes A.; Ishioka C.; Smyth E.	Shitara, K. (12764260600); Fleitas, T. (24070244600); Kawakami, H. (53663802900); Curigliano, G. (57221578995); Narita, Y. (55839842000); Wang, F. (57192698934); Wardhani, S.O. (57193196381); Basade, M. (8088436500); Rha, S.Y. (7006023235); Wan Zamaniah, W.I. (57197752505); Sacdalan, D.L. (57193522866); Ng, M. (56693812000); Yeh, K.H. (7201438906); Sunpaweravong, P. (6508227376); Sirachainan, E. (6602792356); Chen, M.-H. (58434745100); Yong, W.P. (58910827500); Peneyra, J.L. (58910632700); Ibtis	12764260600; 24070244600; 53663802900; 57221578995; 55839842000; 57192698934; 57193196381; 8088436500; 7006023235; 57197752505; 57193522866; 56693812000; 7201438906; 6508227376; 6602792356; 58434745100; 58910827500; 58910632700; 58910037700; 57219957155; 58349814100; 57194732282; 59157671700; 58911235000; 57205400013; 7005105717; 56653172200; 56230606500; 36440260400; 57535599600; 7005354286; 36103192800	Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with gastric cancer	2024	ESMO Open	9	2	102226				2	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85186220766&doi=10.1016%2fj.esmoop.2023.102226&partnerID=40&md5=0c937b4cfa4a40dca0c3591c97c6539e	Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan; Department of Medical Oncology, Hospital Clínico Universitario de Valencia, INCLIVA Biomedical Research Institute, Valencia, Spain; Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka-Sayama, Japan; Istituto Europeo di Oncologia, IRCCS, Milan; Department of Oncology and Haemato-Oncology, University of Milano, Milan, Italy; Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan; Department of Medical Oncology, Sun Yat-sen University Cancer Center, Mainland China, Guangzhou, China; Department of Internal Medicine Division of Medical Hematology-Oncology, Brawijaya University, Dr. Saiful Anwar General Hospital Malang, East Java, Indonesia; Department of Medical Oncology, Jaslok Hospital and Breach Candy Hospital, Mumbai, India; Department of Internal Medicine, Yonsei University College of Medicine, Yonsei Cancer Center, Yonsei University Health System, Seoul, South Korea; Clinical Oncology Unit, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia; Division of Medical Oncology, Department of Medicine, University of the Philippines, The Philippines, Manila, Philippines; Department of GI Oncology, National Cancer Centre Singapore, Singapore, Singapore; Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan; Graduate Institute of Oncology, National Taiwan University College of Medicine, Taipei, Taiwan; Division of Medical Oncology, Department of Medicine, Faculty of Medicine, Prince of Songkla University, Songkhla, Thailand; Division of Medical Oncology, Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand; Department of Oncology, Taipei Veterans General Hospital, Taipei, Taiwan; Department of Haematology-Oncology, National University Cancer Institute, Singapore, Singapore; St. Peregrine Oncology Unit, San Juan de Dios Hospital, The Philippines, Pasay City, Philippines; Institute of Radiotherapy and Oncology, General Hospital Kuala Lumpur, Kuala Lumpur, Malaysia; Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seoul, South Korea; Department of Medical Oncology, AIG Hospital, Hyderabad, India; Division of Gastroenterology, Pancreatobiliary Oncology and Digestive Endoscopy, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia, Dr. Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia; Department of Oncology, University of Tongji, Shanghai East Hospital, Mainland China, Shanghai, China; Section of Medical Oncology, Department of Internal Medicine, Southern Philippines Medical Center ESM, The Philippines, Davao City, Philippines; Department of Oncology and Social Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan; Department of Gastroenterological Chemotherapy, Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan; ESMO, Lugano, Switzerland; Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan; Department of Medical Oncology, INCLIVA Biomedical Research Institute, University of Valencia, Valencia; CIBERONC, Instituto de Salud Carlos III, Madrid, Spain; Department of Medical Oncology, Tohoku University Hospital, Sendai, Japan; Department of Oncology, Oxford University Hospital NHS Foundation Trust, Oxford, United Kingdom	Shitara K., Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan; Fleitas T., Department of Medical Oncology, Hospital Clínico Universitario de Valencia, INCLIVA Biomedical Research Institute, Valencia, Spain; Kawakami H., Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka-Sayama, Japan; Curigliano G., Istituto Europeo di Oncologia, IRCCS, Milan, Department of Oncology and Haemato-Oncology, University of Milano, Milan, Italy; Narita Y., Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan; Wang F., Department of Medical Oncology, Sun Yat-sen University Cancer Center, Mainland China, Guangzhou, China; Wardhani S.O., Department of Internal Medicine Division of Medical Hematology-Oncology, Brawijaya University, Dr. Saiful Anwar General Hospital Malang, East Java, Indonesia; Basade M., Department of Medical Oncology, Jaslok Hospital and Breach Candy Hospital, Mumbai, India; Rha S.Y., Department of Internal Medicine, Yonsei University College of Medicine, Yonsei Cancer Center, Yonsei University Health System, Seoul, South Korea; Wan Zamaniah W.I., Clinical Oncology Unit, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia; Sacdalan D.L., Division of Medical Oncology, Department of Medicine, University of the Philippines, The Philippines, Manila, Philippines; Ng M., Department of GI Oncology, National Cancer Centre Singapore, Singapore, Singapore; Yeh K.H., Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan, Graduate Institute of Oncology, National Taiwan University College of Medicine, Taipei, Taiwan; Sunpaweravong P., Division of Medical Oncology, Department of Medicine, Faculty of Medicine, Prince of Songkla University, Songkhla, Thailand; Sirachainan E., Division of Medical Oncology, Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand; Chen M.-H., Department of Oncology, Taipei Veterans General Hospital, Taipei, Taiwan; Yong W.P., Department of Haematology-Oncology, National University Cancer Institute, Singapore, Singapore; Peneyra J.L., St. Peregrine Oncology Unit, San Juan de Dios Hospital, The Philippines, Pasay City, Philippines; Ibtisam M.N., Institute of Radiotherapy and Oncology, General Hospital Kuala Lumpur, Kuala Lumpur, Malaysia; Lee K.-W., Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seoul, South Korea; Krishna V., Department of Medical Oncology, AIG Hospital, Hyderabad, India; Pribadi R.R., Division of Gastroenterology, Pancreatobiliary Oncology and Digestive Endoscopy, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia, Dr. Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia; Li J., Department of Oncology, University of Tongji, Shanghai East Hospital, Mainland China, Shanghai, China; Lui A., Section of Medical Oncology, Department of Internal Medicine, Southern Philippines Medical Center ESM, The Philippines, Davao City, Philippines; Yoshino T., Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan; Baba E., Department of Oncology and Social Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan; Nakayama I., Department of Gastroenterological Chemotherapy, Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan; Pentheroudakis G., ESMO, Lugano, Switzerland; Shoji H., Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan; Cervantes A., Department of Medical Oncology, INCLIVA Biomedical Research Institute, University of Valencia, Valencia, CIBERONC, Instituto de Salud Carlos III, Madrid, Spain; Ishioka C., Department of Medical Oncology, Tohoku University Hospital, Sendai, Japan; Smyth E., Department of Oncology, Oxford University Hospital NHS Foundation Trust, Oxford, United Kingdom	The European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with gastric cancer (GC), published in late 2022 and the updated ESMO Gastric Cancer Living Guideline published in July 2023, were adapted in August 2023, according to previously established standard methodology, to produce the Pan-Asian adapted (PAGA) ESMO consensus guidelines for the management of Asian patients with GC. The adapted guidelines presented in this manuscript represent the consensus opinions reached by a panel of Asian experts in the treatment of patients with GC representing the oncological societies of China (CSCO), Indonesia (ISHMO), India (ISMPO), Japan (JSMO), Korea (KSMO), Malaysia (MOS), the Philippines (PSMO), Singapore (SSO), Taiwan (TOS) and Thailand (TSCO), coordinated by ESMO and the Japanese Society of Medical Oncology (JSMO). The voting was based on scientific evidence and was independent of the current treatment practices, drug access restrictions and reimbursement decisions in the different Asian regions represented by the 10 oncological societies. The latter are discussed separately in the manuscript. The aim is to provide guidance for the optimisation and harmonisation of the management of patients with GC across the different regions of Asia, drawing on the evidence provided by both Western and Asian trials, whilst respecting the differences in screening practices, molecular profiling and age and stage at presentation. Attention is drawn to the disparity in the drug approvals and reimbursement strategies, between the different regions of Asia. © 2024 The Author(s)	ESMO; gastric cancer; guidelines; Pan-Asian; treatment	Asia; Follow-Up Studies; Humans; Medical Oncology; Societies, Medical; Stomach Neoplasms; cisplatin; docetaxel; epidermal growth factor receptor 2; fluoropyrimidine; gimeracil plus oteracil potassium plus tegafur; irinotecan; oxaliplatin; pembrolizumab; platinum derivative; trastuzumab deruxtecan; adaptation; Article; cancer adjuvant therapy; cancer chemotherapy; cancer diagnosis; cancer staging; cancer surgery; cancer therapy; China; clinical trial (topic); consensus; drug approval; epidemiological data; follow up; histopathology; human; India; Indonesia; Japan; Korea; Malaysia; managed care; methodology; molecular biology; monotherapy; oncology; perioperative care; phase 3 clinical trial (topic); Philippines; practice guideline; public health service; radical gastrectomy; reimbursement;			Elsevier B.V.	20597029	38458658	Article	Q1	2196	1106	View
12776850800; 57210325442; 20733356900; 57200425631; 9939010500; 59125988400; 24400267100(1)
No records
389	Hasan I.; Murti I.S.; Bayupurnama P.; Kalista K.F.; Hill-Zabala C.; Kananda D.; Viayna E.	Hasan, Irsan (12776850800); Murti, Ignatia Sinta (57210325442); Bayupurnama, Putut (20733356900); Kalista, Kemal Fariz (57200425631); Hill-Zabala, Christina (9939010500); Kananda, Dennis (59125988400); Viayna, Elisabet (24400267100)	12776850800; 57210325442; 20733356900; 57200425631; 9939010500; 59125988400; 24400267100	Cost-effectiveness of albumin in the treatment of decompensated cirrhosis in resource-limited healthcare settings	2024	Drugs in Context	13						0	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85193009419&doi=10.7573%2fdic.2024-1-1&partnerID=40&md5=62c68ebeb61f8354101fdd841dd380b8	Hepatobiliary Division, Department of Internal Medicine, Faculty of Medicine, Cipto Mangunkusumo National General Hospital, Universitas Indonesia, Jakarta, Indonesia; Department of Internal Medicine, Abdul Wahab Sjahranie General Hospital Samarinda, East Kalimantan, Indonesia; Gastroenterology & Hepatology Division, Department of Internal Medicine, Dr. Sardjito General Hospital, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia; Grifols Asia Pacific Pte Ltd, Singapore; IQVIA, Jakarta, Indonesia; Grifols SA, Sant Cugat del Vallès, Spain	Hasan I., Hepatobiliary Division, Department of Internal Medicine, Faculty of Medicine, Cipto Mangunkusumo National General Hospital, Universitas Indonesia, Jakarta, Indonesia; Murti I.S., Department of Internal Medicine, Abdul Wahab Sjahranie General Hospital Samarinda, East Kalimantan, Indonesia; Bayupurnama P., Gastroenterology & Hepatology Division, Department of Internal Medicine, Dr. Sardjito General Hospital, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia; Kalista K.F., Hepatobiliary Division, Department of Internal Medicine, Faculty of Medicine, Cipto Mangunkusumo National General Hospital, Universitas Indonesia, Jakarta, Indonesia; Hill-Zabala C., Grifols Asia Pacific Pte Ltd, Singapore; Kananda D., IQVIA, Jakarta, Indonesia; Viayna E., Grifols SA, Sant Cugat del Vallès, Spain	Background: Human albumin (HA) is an effective ad-juvant treatment for patients with cirrhosis developing spontaneous bacterial peritonitis (SBP), hepatorenal syndrome (HRS) and ascites requiring large-volume paracentesis (LVP). However, cost remains a barrier to use, particularly in resource-limited settings. This study aims to assess the cost-effectiveness of HA in patients with cirrhosis with SBP, HRS or ascites requiring LVP in the Indonesian healthcare system as a representative of a resource-limited setting. Methods: Three decision-tree models were developed to assess the cost-effectiveness of (1) antibiotics and HA versus antibiotics alone in patients with SBP, (2) terlipressin and HA versus terlipressin alone in patients with HRS, and (3) LVP and HA versus LVP and gelatine for patients with ascites. Clinical utility and economic inputs were pooled from the available literature. Time horizon was 3 months. Outcomes were expressed as incremental cost-effectiveness ratios (ICER) reported as 2021 IDR per quality-adjusted life year (QALY) (exchange rate June 30, 2021: 1 EUR = 17,245 IDR). Willingness-to-pay thresholds considered were: three times the GDP per capita (199,355,561 IDR/QALY; 11,560 EUR/QALY) and one time the GDP per capita (66,451,854 IDR/QALY; 3853 EUR/QALY). Results: The ICER for antibiotics and HA (versus antibiotics alone) for SBP was 80,562,652 IDR per QALY gained (4672 EUR/QALY). The ICER for terlipressin and HA (versus terlipressin) for HRS was 23,085,004 IDR per QALY gained (1339 EUR/QALY). The ICER for LVP and HA versus LVP and gelatine was 24,569,827 IDR per QALY gained (1425 EUR/QALY). Conclusion: Adjunctive HA may be a cost-effective treatment for SBP, HRS and LVP in resource-limited settings. © 2024 Hasan I, Murti IS, Bayupurnama P, Kalista KF, Hill-Zabala C, Kananda D, Viayna E. Published by Drugs in Context under Creative Commons License Deed CC BY NC ND 4.0, which allows anyone to copy, distribute, and transmit the article provided it is properly attributed in the manner specified below. No commercial use without permission.	cost-effectiveness; human albumin; Indonesia; liver cirrhosis; liver diseases; resource-limited settings	cefotaxime; gelatin; human albumin; terlipressin; Article; ascites; bacterial peritonitis; cost effectiveness analysis; decision tree; decompensated liver cirrhosis; drug cost; drug megadose; economic evaluation; economic model; female; health care system; health care utilization; health economics; hepatic encephalopathy; hepatorenal syndrome; hospitalization; human; hyponatremia; kidney dysfunction; male; monotherapy; paracentesis; quality adjusted life year; survival analysis; treatment duration; Willingness To Pay	Xcenda LLC; Grifols Asia Pacific Pte Ltd	Jordi Bozzo PhD, CMPP (Grifols) is acknowledged for assistance in the preparation of the manuscript. M Chris Runken from Grifols SSNA and Rashad Carlton from Xcenda LLC are acknowledged for their support in the original model development and interpretation. Royasia Ramadani is acknowledged for her support in the literature review and interpretation of results. Prof. Rino Alvani Gani MD, PhD, Prof.	Bioexcel Publishing LTD	17451981		Article	Q2	845	5506	View
13805293700; 6504153311; 7006807491; 23470471000; 7401480880(1)
No records
458	Kavoussi P.; Birowo P.; Saleh R.; Shah R.; Agarwal A.	Kavoussi, Parviz (13805293700); Birowo, Ponco (6504153311); Saleh, Ramadan (7006807491); Shah, Rupin (23470471000); Agarwal, Ashok (7401480880)	13805293700; 6504153311; 7006807491; 23470471000; 7401480880	Varicocele and male infertility conundrum: Making sense of a never-ending story for the busy clinician	2024	Arab Journal of Urology	22	1		1	5	4	0	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85179915951&doi=10.1080%2f20905998.2023.2291628&partnerID=40&md5=f9229d469a72dedc08bf874a715f654a	Department of Reproductive Urology, Austin Fertility & Reproductive Medicine/Westlake IVF, Austin, TX, United States; Global Andrology Forum, OH, United States; Department of Urology, Faculty of Medicine, Universitas Indonesia, Dr. Cipto Mangunkusumo Hospital, Jakarta, Indonesia; Department of Dermatology, Venereology and Andrology, Faculty of Medicine, Sohag University, Sohag, Egypt; Ajyal IVF Center, Ajyal Hospital, Sohag, Egypt; Division of Andrology, Department of Urology, Lilavati Hospital and Research Centre, Mumbai, India; Cleveland Clinic Foundation, Cleveland, OH, United States	Kavoussi P., Department of Reproductive Urology, Austin Fertility & Reproductive Medicine/Westlake IVF, Austin, TX, United States, Global Andrology Forum, OH, United States; Birowo P., Global Andrology Forum, OH, United States, Department of Urology, Faculty of Medicine, Universitas Indonesia, Dr. Cipto Mangunkusumo Hospital, Jakarta, Indonesia; Saleh R., Global Andrology Forum, OH, United States, Department of Dermatology, Venereology and Andrology, Faculty of Medicine, Sohag University, Sohag, Egypt, Ajyal IVF Center, Ajyal Hospital, Sohag, Egypt; Shah R., Global Andrology Forum, OH, United States, Division of Andrology, Department of Urology, Lilavati Hospital and Research Centre, Mumbai, India; Agarwal A., Global Andrology Forum, OH, United States, Cleveland Clinic Foundation, Cleveland, OH, United States	Background: Varicocele is a common occurrence, particularly among men with primary and secondary infertility. There has been extensive research into the management of varicocele in the context of male infertility. Methods: This article aims to explore the variations in clinical practice in diagnosing and managing varicoceles in infertile men. A summary of the current recommendations on varicocele management from professional societies is included. Results: Substantial gaps in knowledge persist regarding varicoceles and male infertility, with significant variation in clinical approaches, despite the wealth of existing data in the medical literature. Conclusion: The existing literature leaves many questions surrounding varicocele management in infertile men unanswered. This lack of clarity contributes to the ongoing controversy among clinicians in the field. New research is essential to address these contentious points and areas of debate. © 2023 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.	Male infertility; oligoasthenoteratozoospermia; varicocele; varicocele repair	follitropin; adult; asthenospermia; azoospermia; case report; clinical article; clinical practice; disease duration; follitropin blood level; human; male; male infertility; medical decision making; medical research; Note; oligoasthenoteratozoospermia; physical examination; semen analysis; testis atrophy; Valsalva maneuver; varicocele; varicocelectomy; vein diameter			Taylor and Francis Ltd.	2090598X		Note	Q3	441	11535	View
14325991900; 57209747495; 55486095900; 57202798959(1)
No records
83	Setiati S.; Ardian L.J.; Fitriana I.; Azwar M.K.	Setiati, Siti (14325991900); Ardian, Laurentius Johan (57209747495); Fitriana, Ika (55486095900); Azwar, Muhammad Khifzhon (57202798959)	14325991900; 57209747495; 55486095900; 57202798959	Improvement of scoring system used before discharge to predict 30-day all-cause unplanned readmission in geriatric population: a prospective cohort study	2024	BMC Geriatrics	24	1	281				0	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85188529298&doi=10.1186%2fs12877-024-04875-9&partnerID=40&md5=70f08a04e28a84f11d5b98d797661f76	Division of Geriatrics, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia-Cipto Mangunkusumo Hospital, Jakarta, Indonesia; Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia-Cipto Mangunkusumo Hospital, Jakarta, Indonesia	Setiati S., Division of Geriatrics, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia-Cipto Mangunkusumo Hospital, Jakarta, Indonesia; Ardian L.J., Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia-Cipto Mangunkusumo Hospital, Jakarta, Indonesia; Fitriana I., Division of Geriatrics, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia-Cipto Mangunkusumo Hospital, Jakarta, Indonesia; Azwar M.K., Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia-Cipto Mangunkusumo Hospital, Jakarta, Indonesia	Background: Data taken from tertiary referral hospitals in Indonesia suggested readmission rate in older population ranging between 18.1 and 36.3%. Thus, it is crucial to identify high risk patients who were readmitted. Our previous study found several important predictors, despite unsatisfactory discrimination value. Methods: We aimed to investigate whether comprehensive geriatric assessment (CGA) -based modification to the published seven-point scoring system may increase the discrimination value. We conducted a prospective cohort study in July–September 2022 and recruited patients aged 60 years and older admitted to the non-surgical ward and intensive coronary care unit. The ROC curve was made based on the four variables included in the prior study. We conducted bivariate and multivariate analyses, and derived a new scoring system with its discrimination value. Results: Of 235 subjects, the incidence of readmission was 32.3% (95% CI 26–38%). We established a new scoring system consisting of 4 components. The scoring system had maximum score of 21 and incorporated malignancy (6 points), delirium (4 points), length of stay ≥ 10 days (4 points), and being at risk of malnutrition or malnourished (7 points), with a good calibration test. The C-statistic value was 0.835 (95% CI 0.781–0.880). The optimal cut-off point was ≥ 8 with a sensitivity of 90.8% and a specificity of 54.7%. Conclusions: Malignancy, delirium, length of stay ≥ 10 days, and being at risk of malnutrition or malnourished are predictors for 30-day all-cause unplanned readmission. The sensitive scoring system is a strong model to identify whether an individual is at higher risk for readmission. The new CGA-based scoring system had higher discrimination value than that of the previous seven-point scoring system. © The Author(s) 2024.	Delirium; Geriatric syndrome; Malnutrition; Older adult; Readmission	Aged; Delirium; Humans; Malnutrition; Middle Aged; Neoplasms; Patient Discharge; Patient Readmission; Prospective Studies; Retrospective Studies; Risk Factors; aged; delirium; hospital discharge; hospital readmission; human; malnutrition; middle aged; neoplasm; prospective study; retrospective study; risk factor			BioMed Central Ltd	14712318	38528454	Article	Q1	1127	3441	View
14527452900; 59139501200; 57223906853; 57790589800; 57359274400; 8917676900(1)
No records
74	Nelwan E.J.; Herdiman A.; Kalaij A.G.I.; Lauditta R.K.; Yusuf S.M.; Suarthana E.	Nelwan, Erni Juwita (14527452900); Herdiman, Allerma (59139501200); Kalaij, Ayers Gilberth Ivano (57223906853); Lauditta, Richella Khansa (57790589800); Yusuf, Syarif Maulana (57359274400); Suarthana, Eva (8917676900)	14527452900; 59139501200; 57223906853; 57790589800; 57359274400; 8917676900	Role of probiotic as adjuvant in treating various infections: a systematic review and meta-analysis	2024	BMC Infectious Diseases	24	1	505				0	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85193922064&doi=10.1186%2fs12879-024-09259-3&partnerID=40&md5=50beaeba11f189e8417c4ef3a4a2f53a	Faculty of Medicine, Universitas Indonesia, DKI Jakarta, 10430, Indonesia; Division of Tropical and Infectious Disease, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia, DKI Jakarta, 10430, Indonesia; Infectious Disease and Immunology Research Center, Indonesia Medical and Education Research Institute (IMERI), Faculty of Medicine, Universitas Indonesia, DKI Jakarta, 10430, Indonesia; Health Technology Assessment Unit (TAU) of the McGill University Health Center, Montreal, Canada	Nelwan E.J., Faculty of Medicine, Universitas Indonesia, DKI Jakarta, 10430, Indonesia, Division of Tropical and Infectious Disease, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia, DKI Jakarta, 10430, Indonesia, Infectious Disease and Immunology Research Center, Indonesia Medical and Education Research Institute (IMERI), Faculty of Medicine, Universitas Indonesia, DKI Jakarta, 10430, Indonesia; Herdiman A., Faculty of Medicine, Universitas Indonesia, DKI Jakarta, 10430, Indonesia; Kalaij A.G.I., Faculty of Medicine, Universitas Indonesia, DKI Jakarta, 10430, Indonesia; Lauditta R.K., Division of Tropical and Infectious Disease, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia, DKI Jakarta, 10430, Indonesia; Yusuf S.M., Infectious Disease and Immunology Research Center, Indonesia Medical and Education Research Institute (IMERI), Faculty of Medicine, Universitas Indonesia, DKI Jakarta, 10430, Indonesia; Suarthana E., Health Technology Assessment Unit (TAU) of the McGill University Health Center, Montreal, Canada	Background: Research on the advantages of probiotics has attracted increasing interest based on the number of publications, products, and public awareness of their benefits. This review evaluated the role of probiotics (single and multiple regimens) as an additional regimen to treat common infectious diseases, including Helicobacter. pylori, diarrheal infections, urinary tract infections (UTIs), upper respiratory tract infections (URTIs), and HIV infections. Methods: We searched randomized controlled trials from PubMed, Scopus, Embase, and Cochrane and identified 6,950 studies. Duplicates were removed, and titles and abstracts were filtered. Bias was evaluated using the Cochrane Risk of Bias Tool for Randomized Trials (ROB 1.0 and 2.0). The certainty of the evidence was evaluated using GRADE. Data were extracted and meta-analysis was performed using RevMan. Results: A total of 32 studies were included in this study (22 H. pylori studies, 2 diarrheal infection studies, 6 UTI studies, and 2 HIV infection studies). There was no study on URTI. Probiotics, in addition to primary treatment, could improve the eradication of H. pylori versus the control (RR: 1.09; 95% CI:1.04 − 1.13, p value = 0.001) and achieve a cure range of Nugent score in UTI patients (RR 1.38; 95% CI: 1.01 − 1.89, p value = 0.04). For eradicating H. pylori infection, subgroup analysis based on the therapy regimen showed that standard triple therapy was slightly superior compared to quadruple therapy in eradicating H. pylori (RR: 1.14 vs. 1.01, respectively). Single strain probiotics showed a similar effect to multiple strain probiotic regimens (both had an RR of 1.09). The effect estimates of the use of single strain probiotics as adjuvant therapy in eradicating H. pylori and the use of probiotics in UTI had a high certainty of evidence. Meta-analysis was not performed for infectious diarrheal because there were only two eligible studies with different probiotic supplementations and outcome parameters. Nonetheless, they showed that the diarrheal incidence was lower and complete remission of diarrheal was higher after the regimen of probiotics. Similarly, a meta-analysis was not performed for HIV infection because the two eligible studies used different designs and comparators with contradicting findings. Conclusion: This meta-analysis showed beneficial use of single strain probiotics as adjuvant therapy in eradicating H. pylori and the use of probiotics in UTI. Probiotic supplementation might not be beneficial for patients given a quadruple therapy. Single-strain and multi-strain probiotic regimens had similar effects in increasing the eradication rate of H. pylori. Our study also suggested that the benefits of probiotics as an additional regimen in infectious diarrheal and HIV infections remain unclear; more studies are needed to confirm the benefits. © The Author(s) 2024.	Diarrheal infection; Helicobacter pylori; Human immunodeficiency virus; Probiotics; Urinary tract infection	Diarrhea; Helicobacter Infections; Helicobacter pylori; HIV Infections; Humans; Probiotics; Randomized Controlled Trials as Topic; Respiratory Tract Infections; Treatment Outcome; Urinary Tract Infections; probiotic agent; probiotic agent; antiretroviral therapy; bacterial clearance; Bifidobacterium; CD4 lymphocyte count; diarrhea; follow up; GRADE approach; Helicobacter infection; human; Human immunodeficiency virus infection; meta analysis; quadruple chemotherapy; quality control; randomized controlled trial (topic); respiratory tract infection; Review; sensitivity analysis; systematic review; urinary tract infection; diarrhea; drug effect; drug therapy; Helicobacter infection; Helicobacter pylori; Human immunodeficiency virus infection; microbiology; prevention and control; respiratory			BioMed Central Ltd	14712334	38773400	Review	Q2	1055	3859	View
14720170400; 57210283261; 57224684808; 57192888533; 37762030000; 55301184300(1)
No records
392	Purwoto G.; Aprilia B.; Kayika I.P.G.; Elvira S.D.; Rahardjo H.E.; Nuranna L.	Purwoto, Gatot (14720170400); Aprilia, Bella (57210283261); Kayika, I. Putu Gede (57224684808); Elvira, Sylvia D. (57192888533); Rahardjo, Harrina E. (37762030000); Nuranna, Laila (55301184300)	14720170400; 57210283261; 57224684808; 57192888533; 37762030000; 55301184300	Surveillance of Indonesian female sexual function after hysterectomy	2024	Indian Journal of Cancer	61	1		98	104	6	0	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85193014722&doi=10.4103%2fijc.IJC_269_21&partnerID=40&md5=bda539257ee3474b176f1c696e93fcec	Department of Obstetrics and Gynecology, Faculty of Medicine, Dr. Cipto Mangunkusumo Hospital, University of Indonesia, Jakarta, Indonesia; Department of Psychiatry, Faculty of Medicine, Dr. Cipto Mangunkusumo Hospital, University of Indonesia, Jakarta, Indonesia; Department of Urology, Faculty of Medicine, Dr. Cipto Mangunkusumo Hospital, University of Indonesia, Jakarta, Indonesia	Purwoto G., Department of Obstetrics and Gynecology, Faculty of Medicine, Dr. Cipto Mangunkusumo Hospital, University of Indonesia, Jakarta, Indonesia; Aprilia B., Department of Obstetrics and Gynecology, Faculty of Medicine, Dr. Cipto Mangunkusumo Hospital, University of Indonesia, Jakarta, Indonesia; Kayika I.P.G., Department of Obstetrics and Gynecology, Faculty of Medicine, Dr. Cipto Mangunkusumo Hospital, University of Indonesia, Jakarta, Indonesia; Elvira S.D., Department of Psychiatry, Faculty of Medicine, Dr. Cipto Mangunkusumo Hospital, University of Indonesia, Jakarta, Indonesia; Rahardjo H.E., Department of Urology, Faculty of Medicine, Dr. Cipto Mangunkusumo Hospital, University of Indonesia, Jakarta, Indonesia; Nuranna L., Department of Obstetrics and Gynecology, Faculty of Medicine, Dr. Cipto Mangunkusumo Hospital, University of Indonesia, Jakarta, Indonesia	Background: Sexual function is one component of quality of life that could be fulfilled by humans. Hysterectomy, which is an operative procedure in women, may cause disturbance in sexual function. Aim: This study aims to determine the surveillance of sexual function after hysterectomy. Methods: This is a cross-sectional study involving 92 gynecological tumor patients who had undergone a hysterectomy by open laparotomy procedure for at least 3 months. Evaluation of sexual dysfunction using the female sexual function index (FSFI-6) questionnaire, which assesses sexual function in the form of sexual disorder, sexual dysfunction, desire disorders, stimulation, orgasm disorders, and pain. The study was conducted in September-November 2018 in Dr. Cipto Mangunkusumo Hospital, Jakarta. The patients were divided into total and radical hysterectomy groups and whether castration was performed. Results: The total group had 71 total hysterectomy and 21 radical hysterectomy patients. Sexual dysfunction (radical hysterectomy 47.6%, n = 10/21; total hysterectomy 28.2%, n = 20/71; castration 33.8%, n = 24/71; and without castration 28.6%, n = 6/21); orgasmic disorders (total hysterectomy 28.2%, n = 20/71; radical hysterectomy 47.6%, n = 10/21; castration 33.8%, n = 24/71; without castration 28.6%, n = 6/21); and pain disorder (radical hysterectomy 28.6%, n = 6/21; compared with 9.9%, n = 7/71 total hysterectomy). Conclusion: No significant differences were found between sexual function after radical hysterectomy and total hysterectomy, as well as between the castration groups. Based on these findings, sexual function is an important reference for health professionals to be considered in conducting counseling before and after surgery. © 2023 Indian Journal of Cancer.	Castration; female sexual function index; radical hysterectomy; sexual function; total hysterectomy	adult; anorgasmia; Article; body mass; castration; cross-sectional study; female; female sexual arousal disorder; Female Sexual Function Index; health practitioner; human; hypoactive sexual desire disorder; hysterectomy; Indonesian; laparotomy; major clinical study; monitoring; ovary cancer; psychogenic pain; pubic symphysis; quality of life; radical hysterectomy; sexual dysfunction; sexual function; total hysterectomy; uterus myoma			Wolters Kluwer Medknow Publications	0019509X	38090969	Article	Q4	246	17024	View
15056701600; 57195516171; 58019738400; 57192888893(1)
No records
461	Rachman A.; Rahmaniyah R.; Khomeini A.; Iriani A.	Rachman, Andhika (15056701600); Rahmaniyah, Rizky (57195516171); Khomeini, Andi (58019738400); Iriani, Anggraini (57192888893)	15056701600; 57195516171; 58019738400; 57192888893	The association between vitamin D deficiency and the clinical outcomes of hospitalized COVID-19 patients	2024	F1000Research	12		394				0	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85186943378&doi=10.12688%2ff1000research.132214.4&partnerID=40&md5=ccc8966a7a1ae51fa3121338e042d1b8	Division of Hematology and Oncology, Department of Internal Medicine, Cipto Mangunkusumo National Referral Hospital, Faculty of Medicine, Universitas Indonesia, Centra Jakarta, DKI Jakarta, Dr, 10430, Indonesia; Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia, DKI Jakarta, Central Jakarta, 10430, Indonesia; Department of Internal Medicine, Wisma Atlet COVID-19 Emergency Hospital, DKI Jakarta, North Jakarta, 14360, Indonesia; Department of Clinical Pathology, Yarsi University, DKI Jakarta, Central Jakarta, 10510, Indonesia	Rachman A., Division of Hematology and Oncology, Department of Internal Medicine, Cipto Mangunkusumo National Referral Hospital, Faculty of Medicine, Universitas Indonesia, Centra Jakarta, DKI Jakarta, Dr, 10430, Indonesia; Rahmaniyah R., Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia, DKI Jakarta, Central Jakarta, 10430, Indonesia; Khomeini A., Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia, DKI Jakarta, Central Jakarta, 10430, Indonesia, Department of Internal Medicine, Wisma Atlet COVID-19 Emergency Hospital, DKI Jakarta, North Jakarta, 14360, Indonesia; Iriani A., Department of Clinical Pathology, Yarsi University, DKI Jakarta, Central Jakarta, 10510, Indonesia	Background: Vitamin D deficiency is an emerging public health problem that affects more than one billion people worldwide. Vitamin D has been shown to be effective in preventing and reducing the severity of viral respiratory diseases, including influenza. However, the role of vitamin D in COVID-19 infection remains controversial. This study aimed to analyze the association of vitamin D deficiency on the clinical outcome of hospitalized COVID-19 patients. Methods: A prospective cohort study was conducted among hospitalized COVID-19 patients at two COVID-19 referral hospitals in Indonesia from October 2021 until February 2022. Results: The median serum 25(OH)D level in 191 hospitalized COVID-19 patients was 13.6 [IQR=10.98] ng/mL. The serum 25(OH)D levels were significantly lower among COVID-19 patients with vitamin D deficiency who had cardiovascular disease (p-value=0.04), the use of a ventilator (p-value=0.004), more severe COVID-19 cases (p-value=0.047), and mortality (p-value=0.002). Furthermore, serum 25(OH)D levels were significantly different between patients with mild and severe COVID-19 cases (p-value=0.019). Serum 25(OH)D levels in moderate and severe COVID-19 cases were significantly different (p-value=0.031). Lower serum 25(OH)D levels were significantly associated with an increased number of comorbidities (p-value=0.03), the severity of COVID-19 (p-value=0.002), and the use of mechanical ventilation (p-value=0.032). Mortality was found in 7.3% of patients with deficient vitamin D levels. However, patients with either sufficient or insufficient vitamin D levels did not develop mortality. Conclusions: COVID-19 patients with vitamin D deficiency were significantly associated with having cardiovascular disease, mortality, more severe COVID-19 cases, and the used of mechanical ventilation. Lower serum 25(OH)D levels were associated with an increased number of comorbidities, COVID-19 severity, and the use of mechanical-ventilation. Thus, we suggest hospitalized COVID-19 patients to reach a sufficient vitamin D status to improve the clinical outcome of the disease. Copyright: © 2024 Rachman A et al.	25(OH)D; clinical outcome; COVID-19; Vitamin D	25 hydroxyvitamin D; SARS-CoV-2 vaccine; adult; Article; artificial ventilation; cardiovascular disease; clinical outcome; cohort analysis; comorbidity; controlled study; coronavirus disease 2019; cross-sectional study; disease severity; female; high flow nasal cannula therapy; hospital patient; human; Indonesia; major clinical study; male; mortality; people by vaccination status; prospective study; vitamin blood level; vitamin D deficiency	Direktorat Riset and Pengembangan, Universitas Indonesia, DRPM UI, (ND-5463/UN2.F1.D1.4/PPM.00.00/2022)	This research was funded by Directorate of Research and Development, Universitas Indonesia’s grant program “Hibah PUTI 2022” (grant number: ND-5463/UN2.F1.D1.4/PPM.00.00/2022).	F1000 Research Ltd	20461402		Article	Q1	871	5242	View
15122639800; 59002254800; 57208821931(1)
No records
7	Lubis A.M.T.; Prasetyo J.; Canintika A.F.	Lubis, Andri Maruli Tua (15122639800); Prasetyo, Joseph (59002254800); Canintika, Anissa Feby (57208821931)	15122639800; 59002254800; 57208821931	Isolated posterior cruciate ligament tears in monozygotic twins: A case report	2024	International Journal of Surgery Case Reports	119		109682				0	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85191328847&doi=10.1016%2fj.ijscr.2024.109682&partnerID=40&md5=0972bb4f235ecada673c2cd82a8c8625	Department of Orthopaedics and Traumatology, Faculty of Medicine, Universitas Indonesia-Cipto Mangunkusumo Hospital, Jakarta, Indonesia	Lubis A.M.T., Department of Orthopaedics and Traumatology, Faculty of Medicine, Universitas Indonesia-Cipto Mangunkusumo Hospital, Jakarta, Indonesia; Prasetyo J., Department of Orthopaedics and Traumatology, Faculty of Medicine, Universitas Indonesia-Cipto Mangunkusumo Hospital, Jakarta, Indonesia; Canintika A.F., Department of Orthopaedics and Traumatology, Faculty of Medicine, Universitas Indonesia-Cipto Mangunkusumo Hospital, Jakarta, Indonesia	Introduction and importance: Posterior cruciate ligament (PCL) tears are not as frequent as anterior cruciate ligament (ACL) tears. They are rare as an isolated injury and more commonly occur in a multi-ligament-injured knee. We reported a case of rupture of PCL in monozygotic twins. Case presentation: A 19-year-old female presented with giving away of her left knee since 4 months ago. She fell from stairs previously. Physical examination demonstrated positive posterior drawer test. Magnetic resonance imaging showed ruptured PCL and lateral meniscal tear. Two months later, her identical twin, also a 19-year old-female, fell from the stairs and complained of giving away. Physical examination showed positive posterior drawer test. Magnetic resonance imaging demonstrated ruptured PCL and lateral meniscal tear. Both patients underwent arthroscopic-assisted PCL reconstruction using gracilis, semitendinosus, and peroneus tendon graft. At one year of follow-up, there were no graft failures. The twins had satisfactory outcome measured by Osteoarthritis Outcome Score (KOOS) and visual analogue scale (VAS). Both were athletes prior to their injury and they returned to sport. Clinical discussion: Although it has never been reported before, this report shows that patients may have genetic predisposition to the incidence of PCL rupture. This is likely because of heritable factors, such as biomechanical, anatomic, anthropometric, and neuromuscular traits. A family history of PCL tear may increase the risk of a PCL tear. Further studies are recommended to examine genetic variants as a risk factor for PCL tears and other knee disorders. Conclusions: Multiple variables may lead to the increased risk of these twins: the combination of improper neuromuscular control, genetic factors, and possibly hormonal factors contributed to their PCL injuries. Further history exploration, lab tests, and genetic analysis should be done to determine the variables. Both patients returned to sports protocol testing and returned to sports one year postoperatively. © 2024	Monozygotic twins; Posterior cruciate ligament tear	adult; arthroscopic surgery; Article; athlete; case report; clinical article; female; follow up; gracilis muscle; human; Knee Injury and Osteoarthritis Outcome Score; knee meniscus rupture; lateral meniscus; monozygotic twins; nuclear magnetic resonance imaging; peroneal muscle; physical examination; posterior cruciate ligament reconstruction; posterior cruciate ligament rupture; quadriceps femoris muscle; return to sport; semitendinous muscle; tendon graft; visual analog scale; young adult			Elsevier Ltd	22102612		Article	Q3	193	19555	View
15137204300; 7007112362; 57226028982; 56784402300; 7005343826; 57197315753; 7007069972; 6602161242; 7005886587; 7003989454; 6701433574; 56893685800; 56009497200; 55634732100; 7004519587(1)
No records
182	Srisawat N.; Gubler D.J.; Pangestu T.; Limothai U.; Thisyakorn U.; Ismail Z.; Goh D.; Capeding M.R.; Bravo L.; Yoksan S.; Tantawichien T.; Hadinegoro S.R.; Rafiq K.; Picot V.S.; Ooi E.E.	Srisawat, Nattachai (15137204300); Gubler, Duane J. (7007112362); Pangestu, Tikki (57226028982); Limothai, Umaporn (56784402300); Thisyakorn, Usa (7005343826); Ismail, Zulkifli (57197315753); Goh, Daniel (7007069972); Capeding, Maria Rosario (6602161242); Bravo, Lulu (7005886587); Yoksan, Sutee (7003989454); Tantawichien, Terapong (6701433574); Hadinegoro, Sri Rezeki (56893685800); Rafiq, Kamran (56009497200); Picot, Valentina Sanchez (55634732100); Ooi, Eng Eong (7004519587)	15137204300; 7007112362; 57226028982; 56784402300; 7005343826; 57197315753; 7007069972; 6602161242; 7005886587; 7003989454; 6701433574; 56893685800; 56009497200; 55634732100; 7004519587	Proceedings of the 6th Asia Dengue Summit, June 2023	2024	PLoS Neglected Tropical Diseases	18	3	e0012060				0	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85189720134&doi=10.1371%2fjournal.pntd.0012060&partnerID=40&md5=92c0c72b535c73a7c1c16e355c31354d	Tropical Medicine Cluster, Center of Excellence in Critical Care Nephrology, Faculty of Medicine, Chulalongkorn University, Excellence Center for Critical Care Nephrology, King Chulalongkorn Memorial Hospital, Thailand; Program in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore; Yong Loo Lin School of Medicine, National University of Singapore, Singapore; Tropical Medicine Cluster, Chulalongkorn University and Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand; Department of Pediatrics, KPJ Selangor Specialist Hospital, Malaysia; Division of Paediatric Pulmonary Medicine and Sleep, Khoo Teck Puat National University Children’s Medical Institute, National University Hospital, Singapore; Research Institute for Tropical Medicine, Manila Metro, Muntinlupa City, Philippines; University of the Philippines Manila, Manila, Philippines; Center for Vaccine Development, Institute of Molecular Biosciences, Mahidol University, Bangkok, Thailand; Division of Infectious Diseases, Department of Medicine and Tropical Medicine Cluster, Chulalongkorn University, Bangkok, Thailand; Department of Child Health, Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia; International Society of Neglected Tropical Diseases, London, United Kingdom; Fondation Merieux, Lyon, France	Srisawat N., Tropical Medicine Cluster, Center of Excellence in Critical Care Nephrology, Faculty of Medicine, Chulalongkorn University, Excellence Center for Critical Care Nephrology, King Chulalongkorn Memorial Hospital, Thailand; Gubler D.J., Program in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore; Pangestu T., Yong Loo Lin School of Medicine, National University of Singapore, Singapore; Limothai U., Tropical Medicine Cluster, Center of Excellence in Critical Care Nephrology, Faculty of Medicine, Chulalongkorn University, Excellence Center for Critical Care Nephrology, King Chulalongkorn Memorial Hospital, Thailand; Thisyakorn U., Tropical Medicine Cluster, Chulalongkorn University and Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand; Ismail Z., Department of Pediatrics, KPJ Selangor Specialist Hospital, Malaysia; Goh D., Division of Paediatric Pulmonary Medicine and Sleep, Khoo Teck Puat National University Children’s Medical Institute, National University Hospital, Singapore; Capeding M.R., Research Institute for Tropical Medicine, Manila Metro, Muntinlupa City, Philippines; Bravo L., University of the Philippines Manila, Manila, Philippines; Yoksan S., Center for Vaccine Development, Institute of Molecular Biosciences, Mahidol University, Bangkok, Thailand; Tantawichien T., Division of Infectious Diseases, Department of Medicine and Tropical Medicine Cluster, Chulalongkorn University, Bangkok, Thailand; Hadinegoro S.R., Department of Child Health, Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia; Rafiq K., International Society of Neglected Tropical Diseases, London, United Kingdom; Picot V.S., Fondation Merieux, Lyon, France; Ooi E.E., Program in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore	The 6th Asia Dengue Summit (ADS) themed “Road Map to Zero Dengue Death” was held in Thailand from 15th–16th June 2023. The summit was hosted by Tropical Medicine Cluster, Chulalongkorn University, Bangkok, Thailand in conjunction with Queen Saovabha Memorial Institute, The Thai Red Cross Society; Faculty of Tropical Medicine, Mahidol University; and the Ministry of Public Health. The 6th ADS was convened by Asia Dengue Voice and Action (ADVA); Global Dengue and Aedes Transmitted Diseases Consortium (GDAC); Southeast Asian Ministers of Education Tropical Medicine and Public Health Network (SEAMEO TROPMED); Fondation Mérieux (FMx) and the International Society for Neglected Tropical Diseases (ISNTD). Dengue experts from academia and research, and representatives from the Ministries of Health, Regional and Global World Health Organization (WHO) and International Vaccine Institute (IVI) participated in the three-day summit. With more than 51 speakers and 451 delegates from over 24 countries, 10 symposiums, and 2 full days, the 6th ADS highlighted the growing threat of dengue and its antigenic evolution, flagged the urgent need to overcome vaccine hesitancy and misinformation crisis, and focused on dengue control policies, newer diagnostics, therapeutics and vaccines, travelassociated dengue, and strategies to improve community involvement. © 2024 Srisawat et al.		Asia, Southeastern; Dengue; Humans; Public Health; Thailand; Travel; World Health Organization; cholera vaccine; influenza vaccine; Meningococcus vaccine; neutralizing antibody; ramucirumab; academia; Aedes; antibody dependent enhancement; antigenicity; Article; artificial ventilation; cardiovascular disease; cerebrovascular accident; cohort analysis; controlled study; dengue; dengue hemorrhagic fever; dengue shock syndrome; Dengue virus; Dengue virus 2; Dengue virus 3; disease surveillance; epidemic; female; fever; genetic regulation; genotype; greenhouse effect; health care personnel; hematocrit; hospitalization; human; immune response; intensive care unit; malaria; microcephaly; misinformation; morbidity; mortality; obesity; prevalence; protein structure; public health; Red Cross; respi			Public Library of Science	19352727	38551892	Article	Q1	1298	2726	View
15728721800; 37067327300; 58865874000; 57477727300; 25936059700; 57211655175; 57192888311; 57215378335; 57219746061; 57371164900; 57225078775; 58866983800; 58867206800; 54893129100; 57207854957; 57207854647; 57216431307; 58606578600; 57194509488; 57221614740; 57190664693; 57210234521; 56780398200; 58865874100; 58866320800; 56993540600(1)
No records
209	Suryana B.P.P.; Hidayat R.; Sarmidi S.; Wibowo S.A.K.; Hamijoyo L.; Rahmadi A.R.; Marpaung B.; Ginting A.R.; Kambayana G.; Kurniari P.K.; Sylvawani M.; Najirman; Suarjana N.; Achadiono D.N.W.; Rahmawati L.D.; Awalia; Suntoko B.; Warlisti I.V.; Nurudhin A.; Prabowo N.A.; Partan R.U.; Reagan M.; Adnan E.; Ongkowijaya J.A.; Akil N.; Pratama M.Z.	Suryana, Bagus Putu Putra (15728721800); Hidayat, Rudy (37067327300); Sarmidi, Sumariyono (58865874000); Wibowo, Suryo Anggoro Kusumo (57477727300); Hamijoyo, Laniyati (25936059700); Rahmadi, Andri Reza (57211655175); Marpaung, Blondina (57192888311); Ginting, Andi Raga (57215378335); Kambayana, Gede (57219746061); Kurniari, Pande Ketut (57371164900); Sylvawani, Mahriani (57225078775); Najirman (58866983800); Suarjana, Nyoman (58867206800); Achadiono, Deddy Nur Wachid (54893129100); Rahmawati, L	15728721800; 37067327300; 58865874000; 57477727300; 25936059700; 57211655175; 57192888311; 57215378335; 57219746061; 57371164900; 57225078775; 58866983800; 58867206800; 54893129100; 57207854957; 57207854647; 57216431307; 58606578600; 57194509488; 57221614740; 57190664693; 57210234521; 56780398200; 58865874100; 58866320800; 56993540600	Characteristics and prevalence of clinical remission of rheumatoid arthritis in a nationwide study from Indonesia	2024	International Journal of Rheumatic Diseases	27	2	e15050				1	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85184193597&doi=10.1111%2f1756-185X.15050&partnerID=40&md5=a4f93ec847a80121dbfe5c302eb1c35b	Rheumatology Division Department of Internal Medicine, Faculty of Medicine Universitas Brawijaya, Saiful Anwar General Hospital, Malang, Indonesia; Rheumatology Division Department of Internal Medicine, Faculty of Medicine Universitas Indonesia, Cipto Mangunkusumo National Central General Hospital, Jakarta, Indonesia; Rheumatology Division Department of Internal Medicine, Faculty of Medicine Universitas Padjadjaran, Hasan Sadikin General Hospital, Bandung, Indonesia; Rheumatology Division Department of Internal Medicine, Faculty of Medicine Universitas Sumatera Utara, Medan, Indonesia; Rheumatology Division Department of Internal Medicine, Faculty of Medicine Universitas Udayana, Sanglah General Hospital Denpasar, Bali, Denpasar, Indonesia; Rheumatology Division Department of Internal Medicine, Faculty of Medicine Universitas Syah Kuala, Banda Aceh, Indonesia; Rheumatology Division Department of Internal Medicine, Faculty of Medicine Universitas Andalas, Padang, Indonesia; Rheumatology Division Department of Internal Medicine, Faculty of Medicine Universitas Lambung Mangkurat, Banjarmasin, Indonesia; Rheumatology Division Department of Internal Medicine, Faculty of Medicine Universitas Gadjah Mada, Yogyakarta, Indonesia; Rheumatology Division Department of Internal Medicine, Faculty of Medicine Universitas Airlangga, Dr Soetomo General Hospital, Surabaya, Indonesia; Rheumatology Division Department of Internal Medicine, Faculty of Medicine Universitas Diponegoro, Dr Kariadi General Hospital, Semarang, Indonesia; Rheumatology Division Department of Internal Medicine, Faculty of Medicine Universitas Sebelas Maret, Dr Moewardi General Hospital, Solo, Indonesia; Rheumatology Division Department of Internal Medicine, Faculty of Medicine Universitas Sriwijaya, Mohammad Hoesin General Hospital, Palembang, Indonesia; Rheumatology Division Department of Internal Medicine, Faculty of Medicine Universitas Hasanudin, Makassar, Indonesia; Rheumatology Division Department of Internal Medicine, Faculty of Medicine Universitas Sam Ratulangi, Manado, Indonesia; Department of Internal Medicine, Kanujoso Djatiwibowo General Hospital, Balikpapan, Indonesia	Suryana B.P.P., Rheumatology Division Department of Internal Medicine, Faculty of Medicine Universitas Brawijaya, Saiful Anwar General Hospital, Malang, Indonesia; Hidayat R., Rheumatology Division Department of Internal Medicine, Faculty of Medicine Universitas Indonesia, Cipto Mangunkusumo National Central General Hospital, Jakarta, Indonesia; Sarmidi S., Rheumatology Division Department of Internal Medicine, Faculty of Medicine Universitas Indonesia, Cipto Mangunkusumo National Central General Hospital, Jakarta, Indonesia; Wibowo S.A.K., Rheumatology Division Department of Internal Medicine, Faculty of Medicine Universitas Indonesia, Cipto Mangunkusumo National Central General Hospital, Jakarta, Indonesia; Hamijoyo L., Rheumatology Division Department of Internal Medicine, Faculty of Medicine Universitas Padjadjaran, Hasan Sadikin General Hospital, Bandung, Indonesia; Rahmadi A.R., Rheumatology Division Department of Internal Medicine, Faculty of Medicine Universitas Padjadjaran, Hasan Sadikin General Hospital, Bandung, Indonesia; Marpaung B., Rheumatology Division Department of Internal Medicine, Faculty of Medicine Universitas Sumatera Utara, Medan, Indonesia; Ginting A.R., Rheumatology Division Department of Internal Medicine, Faculty of Medicine Universitas Sumatera Utara, Medan, Indonesia; Kambayana G., Rheumatology Division Department of Internal Medicine, Faculty of Medicine Universitas Udayana, Sanglah General Hospital Denpasar, Bali, Denpasar, Indonesia; Kurniari P.K., Rheumatology Division Department of Internal Medicine, Faculty of Medicine Universitas Udayana, Sanglah General Hospital Denpasar, Bali, Denpasar, Indonesia; Sylvawani M., Rheumatology Division Department of Internal Medicine, Faculty of Medicine Universitas Syah Kuala, Banda Aceh, Indonesia; Najirman, Rheumatology Division Department of Internal Medicine, Faculty of Medicine Universitas Andalas, Padang, Indonesia; Suarjana N., Rheumatology Division Department of Internal Medicine, Faculty of Medicine Universitas Lambung Mangkurat, Banjarmasin, Indonesia; Achadiono D.N.W., Rheumatology Division Department of Internal Medicine, Faculty of Medicine Universitas Gadjah Mada, Yogyakarta, Indonesia; Rahmawati L.D., Rheumatology Division Department of Internal Medicine, Faculty of Medicine Universitas Airlangga, Dr Soetomo General Hospital, Surabaya, Indonesia; Awalia, Rheumatology Division Department of Internal Medicine, Faculty of Medicine Universitas Airlangga, Dr Soetomo General Hospital, Surabaya, Indonesia; Suntoko B., Rheumatology Division Department of Internal Medicine, Faculty of Medicine Universitas Diponegoro, Dr Kariadi General Hospital, Semarang, Indonesia; Warlisti I.V., Rheumatology Division Department of Internal Medicine, Faculty of Medicine Universitas Diponegoro, Dr Kariadi General Hospital, Semarang, Indonesia; Nurudhin A., Rheumatology Division Department of Internal Medicine, Faculty of Medicine Universitas Sebelas Maret, Dr Moewardi General Hospital, Solo, Indonesia; Prabowo N.A., Rheumatology Division Department of Internal Medicine, Faculty of Medicine Universitas Sebelas Maret, Dr Moewardi General Hospital, Solo, Indonesia; Partan R.U., Rheumatology Division Department of Internal Medicine, Faculty of Medicine Universitas Sriwijaya, Mohammad Hoesin General Hospital, Palembang, Indonesia; Reagan M., Rheumatology Division Department of Internal Medicine, Faculty of Medicine Universitas Sriwijaya, Mohammad Hoesin General Hospital, Palembang, Indonesia; Adnan E., Rheumatology Division Department of Internal Medicine, Faculty of Medicine Universitas Hasanudin, Makassar, Indonesia; Ongkowijaya J.A., Rheumatology Division Department of Internal Medicine, Faculty of Medicine Universitas Sam Ratulangi, Manado, Indonesia; Akil N., Department of Internal Medicine, Kanujoso Djatiwibowo General Hospital, Balikpapan, Indonesia; Pratama M.Z., Rheumatology Division Department of Internal Medicine, Faculty of Medicine Universitas Brawijaya, Saiful Anwar General Hospital, Malang, Indonesia	Aim: To investigate the clinical characteristics, DMARD treatment pattern, remission rate, and factors associated with disease remission of rheumatoid arthritis (RA) patients in Indonesia. Method: A multicenter survey was conducted in 2019–2020 involving 16 hospitals in Indonesia. Inclusion criteria were RA patients who fulfilled the 2010 ACR/EULAR classification criteria, were aged ≥18 years, and have been treated with 1 DMARD or more for at least 6 months, with exclusion criteria being the co-existence of other autoimmune diseases or pain syndromes. Disease activities and remission rate were defined using DAS28-ESR. Results: A total of 870 patients were completed for analysis. Remission was achieved in 24.5% of patients, while low disease activity in 18.5%, moderate disease activity in 44.6%, and high disease activity in 12.4%. The distribution of conventional DMARDs from subjects was methotrexate 69.9%, leflunomide 15.9%, sulfasalazine 12.0%, chloroquine/hydroxychloroquine 8.9%, and cyclosporine 4.8%. Patients treated with biologic DMARDs were only 0.3%. The mean methotrexate dose was 11.2 ± 4.0 mg/week, and the mean methotrexate duration was 45.1 ± 36.6 months. The majority of patients received glucocorticoids (65.5%). 71.1% received DMARD monotherapy, while 28.9% had combined DMARDs. According to the multivariate analysis, delayed time to diagnosis and treatment (>6 months), DMARD monotherapy, and glucocorticoid use were negatively associated with disease remission. Conclusion: The remission rate of Indonesian RA patients is 24.5%, and low disease activity is 18.5%. Methotrexate and leflunomide are the most frequent conventional DMARDs used. Delayed diagnosis, delayed treatment, and DMARD monotherapy contributed to the current low remission rate in Indonesia. © 2024 Asia Pacific League of Associations for Rheumatology and John Wiley & Sons Australia, Ltd.	Indonesia; remission rate; rheumatoid arthritis	chloroquine; cyclic citrullinated peptide antibody; disease modifying antirheumatic drug; glucocorticoid; hydroxychloroquine; leflunomide; methotrexate; methylprednisolone; rheumatoid factor; salazosulfapyridine; adult; Article; autoimmune disease; body mass; DAS28; delayed diagnosis; disease activity; disease duration; educational status; erythrocyte sedimentation rate; female; human; major clinical study; male; monotherapy; multicenter study; observational study; prevalence; remission; retrospective study; rheumatoid arthritis; smoking; therapy delay; visual analog scale	Queen Mary Hospital	The authors thank all Indonesian Rheumatology Association (IRA) members for contributing to this study. The authors also thank all the physicians and residents who helped sample the patients in this study. Also thank you very much for Chak Sing Lau from Queen Mary Hospital, University of Hong Kong for comments and suggestions in improving this article.	John Wiley and Sons Inc	17561841		Article	Q3	715	6929	View

Publikasi Scopus 2024 per tanggal 30 Juni 2024 (499 artikel)